IMMvention Therapeutix, Inc.
Recombinant subunit vaccine antigens targeting conserved influenza epitopes for universal flu vaccination
- Sector
- Biotech
- Headquarters
- DURHAM, NC
- Founded
- 2017
- Latest Form D
- $2M, Jan 2023
- Total capital
- $6.2M
- Federal grants
- $277K
- 1 award · 2018
- Rank in peer group#130 of 392
- Private capital raised
- $5.9M
- 2 Form D · last Jan 2023
- 46 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$3.9M
- Federal grantHealth and Human S · Phase I · Advancing Formulation of STING agonist for Universal Flu Vaccine$277K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
31months
from IMMvention Therapeutix, Inc.’s first federal award to its first private round.
- First federal award · Jun 2018
- Health and Human S · $277K
- First Form D · Dec 2020
- $3.9M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#130 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anil GoyalExecutive Officer, DirectorNamed in SEC Form D filings
- Benjamin ScruggsDirectorNamed in SEC Form D filings
- Jenny TingDirectorNamed in SEC Form D filings
- Lev OsherovichDirectorNamed in SEC Form D filings
- Marilyn ThompsonExecutive OfficerNamed in SEC Form D filings
- Mark VellacaDirectorNamed in SEC Form D filings
Show all 8 people
- Mark VellecaDirectorNamed in SEC Form D filings
- Matthew CohenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingBenzimidazole DerivativesUSPTOApplication PCTUS2023084368
- PendingSubstituted Benzoxazolylamino BenzoxazolesUSPTOApplication 19515191
Related companies, and why
- CEIBA BIO INC.Similar federal contract value in Biotech · null in contracts
- Transtarget IncSimilar federal contract value in Biotech · null in contracts
- RESILIO THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- Myosin Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Applied BioMath, LLCSimilar federal contract value in Biotech · null in contracts
- Obatala Sciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .